Moxiclav Bis (Amoxicillin, Clavulanic Acid)

Amoxicillin inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, preventing the cross‑linking of peptidoglycan strands. This weakens the cell wall, leading to bacterial lysis and death. The accompanying clavulanic acid blocks beta‑lactamase enzymes that some bacteria produce to resist amoxicillin.

The dose of Moxiclav Bis is set by the prescribing clinician based on the type and severity of infection, patient age, weight, renal function, and local antimicrobial guidelines. No universal dosing regimen is provided here; the prescriber tailors therapy to each individual case.

Safety data for Moxiclav Bis in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss risks with the patient and consider alternative therapies if appropriate.

To order Moxiclav Bis, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Moxiclav Bis combines amoxicillin with clavulanic acid, extending coverage to beta‑lactamase‑producing bacteria that plain amoxicillin cannot reliably treat. This broader spectrum can be advantageous for mixed infections, but it may also increase the risk of gastrointestinal side effects compared with amoxicillin alone.

Moxiclav Bis tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or direct sunlight.

Moxiclav Bis is administered orally, usually with a full glass of water. The tablet should be swallowed whole and not crushed or chewed unless specifically instructed by a healthcare professional. Dosing frequency and duration are determined by the prescriber.

Serious risks include severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, liver enzyme elevations, neutropenia, and rare skin disorders like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience difficulty breathing, severe rash, persistent diarrhea, or jaundice.

Moxiclav Bis should be avoided in individuals with a known hypersensitivity to amoxicillin, clavulanic acid, or any other beta‑lactam antibiotics. Patients with a history of severe allergic reactions to penicillins, or those who have experienced serious hepatic or hematologic reactions to similar drugs, should not receive this medication.